The FDA approved pembrolizumab for resectable locally advanced head and neck cancer with PD-L1 expression, based on data from the KEYNOTE-689 phase 3 trial showing improved event-free survival and tumor shrinkage. This approval marks a paradigm shift in perioperative cancer care, offering a new therapeutic option guided by biomarker status.